Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitis

J Am Acad Dermatol. 2010 Sep;63(3):e70-2. doi: 10.1016/j.jaad.2010.02.015.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Chemokine CCL17 / analysis
  • Chemokine CCL17 / blood*
  • Cyclosporine / therapeutic use*
  • Dermatitis, Atopic / blood
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Ki-1 Antigen / analysis
  • Ki-1 Antigen / blood*
  • Male
  • Mycophenolic Acid / therapeutic use*
  • Observer Variation
  • Pilot Projects
  • Prognosis
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Single-Blind Method
  • Tablets, Enteric-Coated
  • Treatment Outcome

Substances

  • Biomarkers
  • Chemokine CCL17
  • Ki-1 Antigen
  • Tablets, Enteric-Coated
  • Cyclosporine
  • Mycophenolic Acid